GSK's RSV vaccine candidate wins FDA priority review status
The US Food and Drug Administration has sent GSK’s potential respiratory syncytial virus vaccine down its speedy review path.
by ulrich quistgaard, translated by daniel pedersen
GSK can look forward to an accelerated approval process with the US Food and Drug Administration, FDA, after the authority has granted its priority review status to the British company’s RSV vaccine candidate.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
GSK takes step toward RSV approval in Japan
For subscribers
.jpg)
GSK boasts 83% efficacy for RSV vaccine candidate
For subscribers
